{"id":20,"date":"2023-09-04T20:51:40","date_gmt":"2023-09-04T20:51:40","guid":{"rendered":"https:\/\/www.merckconnect.com\/bridion\/?page_id=20"},"modified":"2025-07-29T12:28:48","modified_gmt":"2025-07-29T12:28:48","slug":"nmb-recovery-pediatric-patients","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/bridion\/nmb-recovery-pediatric-patients\/","title":{"rendered":"Reversal of Neuromuscular Blockade (NMB) in Pediatric Patients"},"content":{"rendered":"\n\n

Efficacy for BRIDION\u00ae<\/sup> (sugammadex)<\/strong><\/strong><\/h2><\/div>\n\n\n\n

Recovery in pediatric patients<\/strong><\/h1><\/div>\n\n\n\n

Recovery from rocuronium- or vecuronium-induced NMB in pediatric patients aged 2 to <17 years of age.<\/h3><\/div>\n\n\n\n

In a study of randomized pediatric patients 2 to <17 years of age (n=288), BRIDION (vs neostigmine) demonstrated statistically faster recovery to a TOF ratio of \u22650.9 from moderate NMB (reappearance of T2<\/sub>).1<\/sup><\/p>\n\n\n\n\n

<\/div>\n\n\n\n

These effects were consistent across age cohorts studied (2 to <6; 6 to <12; 12 to <17 years of age) and NMBA (rocuronium and vecuronium).1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n\n

Primary efficacy objective: time from start of BRIDION or neostigmine administration to recovery of a TOF ratio \u22650.9<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
<\/div>
\"Geometric<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n\n\n\n

Study design1<\/sup><\/strong><\/h4><\/div>\n\n\n\n

Time to recovery from neuromuscular blockade induced by rocuronium or vecuronium followed by administration of BRIDION or neostigmine was assessed in a randomized, double-blind, active comparator-controlled study. The study was conducted in 288 randomized pediatric patients 2 to <17 years of age, of which 276 patients received treatment (153 boys and 123 girls; ASA class 1, 2, and 3; 89.5% were Caucasian; median weight was 25 kg; median age was 7 years). The primary efficacy objective was to evaluate the effect of BRIDION compared to neostigmine for reversal of moderate neuromuscular blockade as measured by time to recovery to a TOF ratio of \u22650.9.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Recovery from rocuronium- or vecuronium-induced NMB in pediatric patients from birth to <2 years old.<\/h3><\/div>\n\n\n\n

In a study of randomized pediatric patients from birth to <2 years of age (n=145), BRIDION (vs neostigmine) demonstrated statistically faster recovery from moderate NMB.<\/p>\n\n\n\n

<\/div>\n\n\n\n

These effects were consistent across age cohorts studied (birth to 27 days, 28 days to <3 months, 3 months to <6 months, 6 months to <2 years of age).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Primary efficacy objective: time from start of BRIDION or neostigmine administration to recovery from moderate NMB<\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>
\"Ratio<\/picture>

<\/p><\/figcaption><\/figure><\/div>\n\n\n\n

Study design<\/strong><\/h4><\/div>\n\n\n\n

Time to recovery from neuromuscular blockade induced by rocuronium or vecuronium followed by administration of BRIDION or neostigmine was assessed in a randomized, double-blind, active comparator-controlled study. The study was conducted in 145 randomized pediatric patients from birth to <2 years of age, of which 138 patients received treatment (92 boys and 46 girls; ASA class 1, 2, and 3; 68% were White; median weight was 5.8 kg; median age was 100.5 days). The primary efficacy objective was to evaluate the time to neuromuscular recovery of BRIDION in comparison to neostigmine for the reversal of moderate neuromuscular blockade.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Abbreviations<\/strong><\/h2><\/div>\n\n\n\n\n